Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Latest filing published 18 Sept 2026 for CRESCENT BIOPHARMA, INC., €3,724. Read the official filing
Filing timeline
BuySaleRyan Lynch
Insider track record
Disclosed buys
0
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Ryan Lynch: trading record in brief
All filings by Ryan Lynch on record concern Crescent Biopharma, Inc. We count 3 filings; the first trade dates from 15 December 2025 and the latest from 16 September 2026.
On the market, this insider has only sold: 2 sales, €3,724 in total. The totals do not cover 1 filing with an undisclosed amount. Other entries cover 1 share grant. So far in 2026, the count stands at no purchases and 2 sales.
The latest filing, published on 18 September 2026, reports an open-market sale of €3,724 in Crescent Biopharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Ryan Lynch
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
240 shares@ US$17.90Ordinary SharesSEC:0001628280-26-062709:0
465 sharesOrdinary SharesSEC:0001628280-26-044893:0
8,378 sharesOrdinary SharesSEC:0001628280-25-057671:0
3 of 3 declarations
